BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023

DJ BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023

-- In France, following three consecutive quarters of growth, revenues increased by +5.2% to EUR14.1m.In the second half of 2023, EBITDA rose by +2.9% to EUR7.8m, giving an EBITDA margin of 23.5%, benefiting from the combined effect of a sharper increase in business and the management of operating costs over the period. This rate of growth will be stable on a like-for-like basis in 2024 and will be +11.2 points higher sequentially than in the first half of 2023.

Thanks to good momentum for the year ahead and although it is advisable to remain cautious given the ongoing macro-economic uncertainties, Bilendi is relatively confident in its ability to continue to generate growth accompanied by sustained profitability in 2024. Other major innovations will also be announced over the course of the year to continue revolutionising the market research sector.Bilendi is reaffirming its aggressive growth strategy combining development and targeted acquisitions with the aim of achieving sales of EUR100m by 2026, and EBITDA of 20% to 25% of sales, i.e., EUR20m to EUR25m.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Sinopec Achieved Solid 2023 Operating ResultsChina Petroleum & Chemical Corporation (Sinopec Corp.) announced its annual results for the year 2023. The company achieved solid operating results with a focus on shareholders' returns. The dividend payout exceeded 70%.
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »

BioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateAdvanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business UpdateConference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company specializing
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »

Ainos, Inc.: Ainos Reports Full Year 2023 Financial ResultsStrategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding market of AI Nose-powered VOC-sensing technology
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »

Grupo Clarín S.A.: Grupo Clarín Announces Full Year and Last Quarter 2023 ResultsBUENOS AIRES, ARGENTINA / ACCESSWIRE / March 8, 2024 / Grupo Clarín S.A. ('Grupo Clarín' or the 'Company') (LSE:GCLA)(BCBA:GCLA), the largest media company in Argentina, announced today its Full Year and
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »